Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:AKBA's Cash to Debt is ranked higher than
71% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:AKBA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: 12424.6
Current: No Debt
N/A
12424.6
Interest Coverage No Debt
NAS:AKBA's Interest Coverage is ranked higher than
62% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -0.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -86.81
NAS:AKBA's ROE (%) is ranked lower than
77% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. NAS:AKBA: -86.81 )
Ranked among companies with meaningful ROE (%) only.
NAS:AKBA' s ROE (%) Range Over the Past 10 Years
Min: -86.81  Med: -51.66 Max: -51.66
Current: -86.81
-86.81
-51.66
ROA (%) -66.24
NAS:AKBA's ROA (%) is ranked lower than
77% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. NAS:AKBA: -66.24 )
Ranked among companies with meaningful ROA (%) only.
NAS:AKBA' s ROA (%) Range Over the Past 10 Years
Min: -365.24  Med: -61.1 Max: -47.82
Current: -66.24
-365.24
-47.82
ROC (Joel Greenblatt) (%) -9603.27
NAS:AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:AKBA: -9603.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:AKBA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -106220  Med: -31616.67 Max: -9603.27
Current: -9603.27
-106220
-9603.27
GuruFocus has detected 2 Warning Signs with Akebia Therapeutics Inc $NAS:AKBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

AKBA Guru Trades in Q4 2015

Steven Cohen 42,000 sh (New)
Jim Simons 109,200 sh (-1.36%)
» More
Q1 2016

AKBA Guru Trades in Q1 2016

Paul Tudor Jones 18,498 sh (New)
Jim Simons 28,500 sh (-73.90%)
Steven Cohen 100 sh (-99.76%)
» More
Q2 2016

AKBA Guru Trades in Q2 2016

Paul Tudor Jones 18,798 sh (+1.62%)
Steven Cohen Sold Out
Jim Simons 24,300 sh (-14.74%)
» More
Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CRIS, NAS:NVAX, NAS:LJPC, NAS:BSTC, NAS:NSTG, NAS:NERV, NAS:CCXI, NAS:TLGT, NAS:SPPI, NAS:FOMX, NAS:XBIT, NAS:MYOK, NAS:MRUS, NAS:NOVN, NAS:PDLI, NAS:TRVN, NAS:CLDX, AMEX:BTX, NAS:MACK, NAS:OMER » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history
P/B 3.52
AKBA's P/B is ranked lower than
52% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. AKBA: 3.52 )
Ranked among companies with meaningful P/B only.
AKBA' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.5
Current: 3.52
0
9.5
Current Ratio 6.32
AKBA's Current Ratio is ranked higher than
63% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AKBA: 6.32 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 6.32  Med: 13.97 Max: 26.43
Current: 6.32
6.32
26.43
Quick Ratio 6.32
AKBA's Quick Ratio is ranked higher than
64% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AKBA: 6.32 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 6.32  Med: 13.97 Max: 26.43
Current: 6.32
6.32
26.43

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.93
AKBA's Price/Net Cash is ranked higher than
65% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. AKBA: 3.93 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 2.49 Max: 4.71
Current: 3.93
2.02
4.71
Price/Net Current Asset Value 3.77
AKBA's Price/Net Current Asset Value is ranked higher than
66% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. AKBA: 3.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.99  Med: 2.43 Max: 4.65
Current: 3.77
1.99
4.65
Price/Tangible Book 3.63
AKBA's Price/Tangible Book is ranked higher than
56% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. AKBA: 3.63 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.98  Med: 2.4 Max: 4.63
Current: 3.63
1.98
4.63
Earnings Yield (Greenblatt) (%) -62.58
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. AKBA: -62.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -132.22  Med: 0 Max: 0
Current: -62.58
-132.22
0

More Statistics

EPS (TTM) $ -3.28
Short Percentage of Float4.85%
52-Week Range $7.00 - 11.07
Shares Outstanding (Mil)38.32

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 63 117 114
EPS ($) -1.93 -1.49 -2.19 -1.13
EPS w/o NRI ($) -1.93 -1.49 -2.19 -1.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge Jan 18 2017
Moving Average Crossover Alert: Akebia (AKBA) Jan 11 2017
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session Jan 03 2017
Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy? Dec 30 2016
Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue? Dec 29 2016
Top Ranked Momentum Stocks to Buy for December 28th Dec 28 2016
Akebia Therapeutics Inc (AKBA) Sells Partial US Rights For Vadadustat To Otsuka Dec 21 2016
Akebia Therapeutics (AKBA) in Focus: Stock Jumps 19.4% Dec 21 2016
Akebia Therapeutics Jumps on License and Collaboration Deal Dec 20 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in... Dec 20 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 20 2016
Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights Dec 20 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in... Dec 20 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in... Dec 20 2016
Is Akebia Therapeutics Inc (AKBA) A Good Stock To Buy? Dec 17 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)